API | sgn-15

sgn-15 Report issue

Biologics mAb ADC Experimental

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

bms-182248

sgn-15

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: No
Payload: doxorubicin
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

bms 182248 | bms-182248 | br96 | br-96 cbr96-doxorubicin immunoconjugate | br96-doxorubicin immunoconjugate | cbr96-doxorubicin immunoconjugate | sgn-15 | sng-15

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue